| Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy D Dytfeld, M Luczak, T Wrobel, L Usnarska-Zubkiewicz, ... Oncotarget 7 (35), 56726, 2016 | 65 | 2016 |
| Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma JK Jasielec, T Kubicki, N Raje, R Vij, D Reece, J Berdeja, BA Derman, ... Blood, The Journal of the American Society of Hematology 136 (22), 2513-2523, 2020 | 62 | 2020 |
| Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous … BA Derman, AT Stefka, K Jiang, A McIver, T Kubicki, JK Jasielec, ... Blood Cancer Journal 11 (2), 19, 2021 | 44 | 2021 |
| Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS … D Dytfeld, T Wróbel, K Jamroziak, T Kubicki, P Robak, A Walter-Croneck, ... The Lancet Oncology 24 (2), 139-150, 2023 | 22 | 2023 |
| Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. M Łuczak, T Kubicki, Z Rzetelska, T Szczepaniak, ... Polish Archives of Internal Medicine 127 (6), 392-400, 2017 | 20 | 2017 |
| Chromosome 1 amplification has similar prognostic value to del (17p13) and t (4; 14)(p16; q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma … N Grzasko, R Hajek, M Hus, S Chocholska, M Morawska, K Giannopoulos, ... Leukemia & lymphoma 58 (9), 2089-2100, 2017 | 17 | 2017 |
| Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on … BA Derman, AT Stefka, A McIver, K Jiang, T Kubicki, J Jasielec, ... Journal of Clinical Oncology 38 (15_suppl), 8513-8513, 2020 | 9 | 2020 |
| High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell … I Hus, J Mańko, D Jawniak, A Jurczyszyn, G Charliński, ... Oncology Letters 18 (6), 5811-5820, 2019 | 7 | 2019 |
| Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests T Kubicki, D Dytfeld, A Baszczuk, E Wysocka, M Komarnicki, ... Advances in Hygiene and Experimental Medicine 71, 40-46, 2017 | 5 | 2017 |
| Bortezomib-and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response T Kubicki, K Bednarek, M Kostrzewska-Poczekaj, M Luczak, ... American Journal of Cancer Research 12 (7), 3280, 2022 | 4 | 2022 |
| Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement T Kubicki, L Gil, D Dytfeld Pol Arch Intern Med 131 (4), 361-8, 2021 | 4 | 2021 |
| G6PD deficiency—does it alter the course of COVID-19 infections? TY Au, OW Wiśniewski, S Benjamin, T Kubicki, D Dytfeld, L Gil Annals of Hematology 102 (7), 1629-1636, 2023 | 3 | 2023 |
| Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either … T Kubicki, D Dytfeld, T Wróbel, K Jamroziak, P Robak, J Czyż, ... British Journal of Haematology 203 (5), 792-802, 2023 | 2 | 2023 |
| ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma. D Dytfeld, T Wrobel, K Jamroziak, T Kubicki, P Robak, J Czyz, ... Journal of Clinical Oncology 40 (16_suppl), 8001-8001, 2022 | 2 | 2022 |
| Comparative proteomic profiling of sera from patients with refractory multiple myeloma for predicting response to bortezomib-based therapy M Luczak, T Kubicki, Z Rzetelska, T Szczepaniak, ... Pol Arch Intern Med 127 (6), 392-400, 2017 | 2 | 2017 |
| Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell … BA Derman, JH Cooperrider, J Rosenblatt, D Avigan, MM Rampurwala, ... Blood 142, 4747, 2023 | 1 | 2023 |
| OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma A Jakubowiak, T Wrobel, K Jamroziak, T Kubicki, P Robak, J Czyz, ... Clinical Lymphoma Myeloma and Leukemia 22, S6, 2022 | 1 | 2022 |
| Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial T Kubicki, D Dytfeld, D Barnidge, DJ Sakrikar, G Lakos, ... Blood 142, 340, 2023 | | 2023 |
| Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide … T Kubicki, BA Derman, K Jamroziak, P Robak, J Czyz, A Tyczynska, ... Blood 142, 3344, 2023 | | 2023 |
| Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone … T Kubicki, D Dytfeld, T Wrobel, K Jamroziak, P Robak, J Czyz, ... Blood 142, 4715, 2023 | | 2023 |
Dominik DytfeldMD PhDVerified email at ump.edu.pl
Dominik DytfeldMD PhDVerified email at ump.edu.pl